AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

source: news (news:seeking-alpha)published 2026-08-17 06:24ingested 2026-08-17 06:40

retained text

Search fieldHome page Seeking Alpha - Power to InvestorsAbout PremiumCreate free accountSearch for Symbols, analysts, keywordsLog in

AstraZeneca halts eVOLVE-Lung02 trial of volrustomig combo

Aug 17, 2026, 2:24 AM ETAstraZeneca PLC (AZN) StockBy : Arundhati Sarkar, SA News Editor

AstraZeneca (AZN) is discontinuing its eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer after an independent committee concluded the drug was unlikely to meet either primary endpoint, according to a statement on Monday.

The

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search fieldEntering text into the input field will update the search result below

Recommended For You

document fetched 2026-08-17 06:40 · canonical https://seekingalpha.com/news/4633649-astrazeneca-halts-evolve-lung02-trial-of-volrustomig-combo?feed_item_type=news